FDA's OK could be start of KV's comeback

An inspection thumbs-up from the FDA last week for KV Pharma's Micro-K manufacturing ops marks a milestone in the drugmaker's GMP-violations comeback. The approval gives KV the go-ahead to produce Micro-K, a treatment for low blood potassium.

The approval follows a mid-August inspection that encompassed quality systems, manufacturing processes and facilities, all of which passed FDA muster. "The inspection was successfully completed without the issuance of a FDA 483," the drugmaker trumpets in an announcement. It expects to begin shipping Micro-K this week.

But it's still a partial comeback for KV at this point. More FDA inspections lie ahead for other products. And the outcomes of those inspections will determine whether the agency gives the go-ahead for their manufacturing and marketing.

The company's troubles date from the 2008 recalls of products made at a Missouri generics facility. The recalls were followed by the FDA's seizure of $24 million in products and its shutdown of the plant, as reported.

- here's the KV release
- see more from Reuters

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.